Nu-Med Plus, Inc. (NUMD) Stock Price & Analysis

Nu-Med Plus, Inc. (NUMD) rose 21.05% to USD 0.02 as of July 25, 2026 at 06:11 UTC, according to Nexqual real-time market data.

NUMD last closed at USD 0.02; the session ranged USD 0.02–0.02 on volume of 3,939 shares. Market capitalization is $1.54M, with a 52-week range of USD 0.01–0.05 (OQB). Source: Nexqual, July 25, 2026 at 06:11 UTC.

Key Statistics (as of July 25, 2026 at 06:11 UTC)

Technical Analysis (NUMD)

Nexqual's technical model rates NUMD "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of July 25, 2026 at 06:11 UTC.

Analyst Ratings (NUMD)

Wall Street analysts rate NUMD "None", per Nexqual as of July 25, 2026 at 06:11 UTC.

Earnings (NUMD)

Source: Nexqual, July 25, 2026 at 06:11 UTC.

Financials & Fundamentals (NUMD)

Source: Nexqual, July 25, 2026 at 06:11 UTC.

Financial Health Score (NUMD)

Nexqual rates Nu-Med Plus, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 06:11 UTC.

Ownership (NUMD)

Source: Nexqual, July 25, 2026 at 06:11 UTC.

Leadership (NUMD)

Nu-Med Plus, Inc. is led by William R. Colvin (age 65), President, CEO & Director, per Nexqual as of July 25, 2026 at 06:11 UTC.

From Nu-Med Plus, Inc.'s Latest SEC 10-K Filing (filed 2026-04-15)

Key Strengths & Strategy (as disclosed to the SEC)

• The FDA has approved the GeNOsyl Advanced Delivery System (ADS) for use with neonates.   Beyond Air (formerly AIT Therapeutics) (AITB) is a company that has acquired technology that produces nitric oxide from air through electrical discharge.
• Both the FDA and the OPRR are in the Department of Health and Human Services.
• We are currently working to secure funding that will enable us to submit the hospital unit for FDA approval.   Current Product Development Status   Following is a discussion of the development state of each of the products.
• As we do not currently have the capital to engage in any regulatory approval, for the foreseeable future we will be focused on the development of our technology and additional patent applications.   Clinical testing, manufacturing and marketing of human pharmaceutical products require prior approval from the FDA and comparable agencies in foreign countries.

Partnerships

• The clinical study program is developed by the company in conjunction with clinician investigators, all in close collaboration with the FDA/CDRH.   The first and arguably most important step in this process is the pre-IDE meeting, in which the company, often accompanied by the lead clinical investigator(s), meets with the FDA/CDRH to present data about the device, its clinical development program, and its intended use after approval.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:11 UTC. This page is informational and not investment advice.